Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2017/V14/I11/699

[1] 杨华, 魏晶, 王嘉仡,等. 药品不良反应/事件报告评价方法研究[J]. 中国药物警戒, 2009, 6(10):581-584.
[2] 国家食品药品监督管理局药品安全监管司,国家药品不良反应中心. 药品不良反应报告和监测工作手册[S]. 2005: 46.
[3] 兰茜, 翟所迪, 何榕. 疑似米力农注射液致QT间期延长1例[J]. 中国药物警戒, 2014, 11(02):123-124.
[4] 邵红银, 徐玉红, 贺华香. 米力农注射液不良反应影响因素Logistic回归分析[C]. 中华医学会西湖重症医学论坛、2015年浙江省重症医学学术年会. 2015:11-16.
[5] 苏广珠, 贺坤. 米力农注射液致低血压休克2例[J]. 中国实用医药, 2014, 9 (17): 175-176.
[6] Berry L L, Segal R, Sherrin T P, et al. Sensitivity and specificity of three methods of detecting adverse drug reactions[J]. American Journal of Hospital Pharmacy, 1988, 45(7): 1534.
[7] 刘敏,李忠东. 实例探讨药物引起SJS或TEN的评分方法-Naranjo评分与ALDEN评分比较[J]. 中国药物应用与监测,2014, 11(4): 247-249.
[8] 毕玉侠. 我国药品不良反应评价研究[D]. 沈阳药科大学, 2010:67-68.
[9] 刘建平, 邢建民. 循证的药品不良反应评价方法[J]. 中国药物警戒, 2010, 7(1):12-15.
[10] 官真水, 林海霞, 蔡琦. 米力农静脉泵入致心房扑动1例[J]. 中国药业, 2015, 24(24).
[11] 孙睦. 米力农静脉泵入诱发冠心病患者心房颤动[J]. 药物不良反应杂志, 2010, 12(2):139-140.
[12] 李素婷. 药源性低血压的病因、临床表现及预防. 中国中医药现代远程教育, 2009,7(1):121.
[13] 斯威曼. 马丁代尔药物大典[M]. 北京：化学工业出版社, 2014:1289.
[14] 中华医学会心血管病学分会. 中国心力衰竭诊断和治疗指南2014[J]. 中华心血管病杂志, 2014, 42(2):3-10.
[15] Yancy C W, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Journal of the American College of Cardiology, 2013, 128(16):e240.
[16] 王兴胜, 陈曦, 王洪群, 等. 乳酸米力农微泵持续注射改善老年慢性肺心病心衰的近期疗效[J]. 老年医学与保健, 2015, 21(5):296-298.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.